Maeda Pharmaceutical Industry Co., Ltd. announced that it expects to receive funding from Iwaki & Co., Ltd.
January 26, 2020
Share
Maeda Pharmaceutical Industry Co., Ltd. announced that it will receive funds in an equity round of funding on January 27, 2020. The transaction will include participation from Iwaki & Co., Ltd. (TSE:8095).
Astena Holdings Co Ltd, formerly Iwaki & Co Ltd is a Japan-based company primarily engaged in the fine chemicals business, medical business, health & beauty care (HBC) and food business, and industrial chemicals business. The Company operates through four business segments. The Fine Chemicals segment is engaged in manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, as well as to printed circuit board and other manufacturing plants. The other businesses include consulting services and others.
ASTENA HOLDINGS CO., LTD. 
